Details of the Drug Reposition

General Information of This Drug (ID: DMMPSA1)

Drug Name
Tusamitamab ravtansine   DMMPSA1
Synonyms SAR408701
Drug Type
Antibody drug conjugate

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-small-cell lung cancer DISI0V1B 2C25 Phase 3 [1]
------------------------------------------------------------------------------------
3 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Aggressive cancer DISKUCQY 2A00-2F9Z Phase 2 [2]
Gastric cancer DISXGOUK 2B72 Phase 2 [3]
Breast cancer DIS7DPX1 2C60-2C65 Phase 2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT05245071) Open-label, Phase 2 Study, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine in Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04659603) Open-label, Multi-cohort, Phase 2 Trial, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine (SAR408701) Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors. U.S.National Institutes of Health.
3 ClinicalTrials.gov (NCT05703555) INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701. U.S.National Institutes of Health.